Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1992-05-12
1993-11-30
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3120
Patent
active
052665941
ABSTRACT:
Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.
REFERENCES:
Albin et al., 1990, "Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease," N. Engl. J. Med., 322:1293-1298.
Beal et al., 1991, "Chronic quinolinic acid lesions in rats closely mimic Huntington's disease," J. Neuroscience, 11:1649-1659.
Beal et al., 1989, "Quinolinic acid striatal lesions in primates as a model of Huntington's disease," Ann. Neurol., 26:137.
Choi, 1990, "Methods for antagonizing glutamate neurotoxicity," Cerebrovasc. Brain Metab. Rev., 2:105-147.
Choi, 1988, "Glutamate neurotoxicity and diseases of the nervous system," Neuron, 1:623-634.
Coyle and Schwarcz, 1976, "Lesions of striatal neurons with kainic acid provides a model for Huntington's chorea," Nature, 263:244-246.
Greenamyre et al., 1985, "Alterations in L-glutamate binding in Alzheimer's and Huntington's disease," Science, 227:1496-1499.
Gardiner et al., 1990, "Regional and cardiac haemodynamic effects of N.sup.G -nitro-L-arginine methyl ester in conscious, Long Evans rats," Br. J. Pharmacol., 101(3):625-631.
McGeer and McGeer, 1976, "Alterations in L-glutamate binding in Alzheimer's and Huntington's disease," Science, 227:1496-1499.
Plaitakis and Yahr, 1982, "Abnormal glutamate metabolism in an adult-onset degenerative neurological disorder," Science, 216:193-196. References Implicating Glutamate Neurotoxicity in Neurodegenerative Disease.
Plaitakis et al., 1988, "The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis," Ann. Neurol., 24:445-449.
Rothstein et al., 1990, "Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis," Ann. Neurol., 28:18-25.
Schwarcz et al., 1983, "Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain," Science, 219:316-318.
Young, 1988, "NMDA receptors losses in putamen from patients with Huntington's disease," Science, 241:981-983.
Dawson et al., Proc. Natl. Acad. Sci. USA, 1991, 88:6368-6371.
Dawson et al., J. Neuroscience, in press, 1993.
Nowicki et al., Eur. J. Pharmac., 1991, 204:339-340.
Trifiletti, Eur. J. Pharmac. 1992, 218:197-198.
Chem. Abst. 114-59571n (1991).
Useful Information On Alzheimer's Disease, U.S. Dept. HHS (1990).
Bredt David S.
Dawson Ted M.
Dawson Valina L.
London Edythe D.
Snyder Solomon H.
LandOfFree
Inhibitors of nitric oxide synthase and use thereof to prevent g does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of nitric oxide synthase and use thereof to prevent g, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of nitric oxide synthase and use thereof to prevent g will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2096714